The results of the study showed that rIL7/IL15 inhibited tumour growth in a dose-dependent manner by approximately 60% at the 2.5 μg level and >80% at the 20 μg level, which are both superior to cytokine monotherapy in terms of anti-tumour effect [95]. Here, IL15 is linked to neoplasm.